Comparison 1.

Rifabutin vs rifampicin

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Cure	2	553	Risk Ratio (M‐H, Fixed, 95% CI)	1.00 [0.96, 1.04]
1.1 Rifabutin 150 mg	1	191	Risk Ratio (M‐H, Fixed, 95% CI)	1.01 [0.95, 1.08]
1.2 Rifabutin 300 mg	2	362	Risk Ratio (M‐H, Fixed, 95% CI)	0.99 [0.94, 1.04]
2 Relapse	2	448	Risk Ratio (M‐H, Fixed, 95% CI)	1.23 [0.45, 3.35]
2.1 Rifabutin 150 mg	1	183	Risk Ratio (M‐H, Fixed, 95% CI)	0.98 [0.09, 10.55]
2.2 Rifabutin 300 mg	2	265	Risk Ratio (M‐H, Fixed, 95% CI)	1.29 [0.43, 3.92]
3 M. tuberculosis culture status 2 months after starting therapy	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
4 M. tuberculosis culture status 3 months after starting therapy	2	654	Risk Ratio (M‐H, Fixed, 95% CI)	1.00 [0.98, 1.03]
4.1 Rifabutin 150 mg	1	228	Risk Ratio (M‐H, Fixed, 95% CI)	1.01 [0.97, 1.06]
4.2 Rifabutin 300 mg	2	426	Risk Ratio (M‐H, Fixed, 95% CI)	1.00 [0.97, 1.03]
5 Adverse events	3	714	Risk Ratio (M‐H, Fixed, 95% CI)	1.42 [0.88, 2.31]
5.1 Rifabutin 150 mg	2	264	Risk Ratio (M‐H, Fixed, 95% CI)	0.98 [0.45, 2.12]
5.2 Rifabutin 300 mg	2	450	Risk Ratio (M‐H, Fixed, 95% CI)	1.78 [0.94, 3.34]